Why OLMA Stock dropped -4.50% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, OLMA scores 31 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 6 / 20. Per the RQD rating, ROIC is -32.8% and FCF yield is -22.88%. For a prospective investor, these figures indicate the business is currently consuming capital rather than generating it, so the valuation rests on future outcomes not yet visible in reported cash flows.
• Whale 13F Flow: 5 / 20. The RQD rating summarizes this pillar as institutional accumulation and options positioning. The underlying holder detail is not provided in this dataset (see Analyst View & Smart Money Ownership), so the score can be noted but not independently traced.
• Insider Conviction: 3 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. It is the lowest-scoring pillar, which indicates weak insider signaling in the provided data.
• Macro Regime Fit: 7 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity noted. A beta of 1.0 means the stock is expected to move in line with the broader market, offering no defensive cushion.
• Forensic Balance Sheet: 10 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. The Piotroski score is weak, and the balance sheet pillar is the highest-scoring of the five but still sits at half its maximum.

Taken together, the pillars point to a company with heavy operating losses, weak insider and cash-flow signals, and a forensic profile that the rating treats as high risk. Upside would depend on factors outside the reported financials, such as future clinical or commercial developments, which this dataset does not describe. Valuation tradeoffs are significant: at a market cap of $641.4M with negative cash flow, the stock's value is highly sensitive to future funding needs and the timing of any revenue inflection.

Olema Pharmaceuticals Inc. is a NASDAQ-listed company in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The source data does not describe its products, customers, or revenue model. Per the SEC financials, reported revenue is $0.0M in each of the listed periods, so the source data does not show a commercial revenue stream.

Per the SEC financials, the company reported operating losses across all three periods, widening from $-105.0M in FY 2023 to $-178.7M in FY 2025. Gross, operating, and net margins are each listed as 0% in the market data. Per the Roarable RQD rating, ROIC is -32.8%, the Altman Z-Score is 2.5, and the Piotroski F-Score is 2/9. Cash declined from $139.5M in FY 2024 to $48.3M in FY 2025 per the SEC financials, and debt is not available in source data.

The news wire contains six headlines, all tagged to OLMA and all rated YELLOW by the source feed. Headlines reference a StockInvest.us price forecast, a TradingView estimates report, a MarketBeat report noting a 3.4% price rise, a MarketBeat report citing a consensus price target of $40.60, a Benzinga pre-market mover list, and a MarketBeat report noting a 7.4% share rise. The summaries are generic and do not describe specific clinical, regulatory, or financing events. The headlines provide no verifiable catalyst details beyond these market-action references. Per the Butterfly Supply-Chain Graph, there are no supply-chain links and no proprietary signals. Watch item: the consensus target cited in a headline ($40.60) is well above the $7.33 price, but the analyst data section is empty, so the target cannot be verified.

Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. The only sector context provided is the Health Care sector classification and the beta of 1.0.

• What are the company's commercial products or pipeline stage, and is there any path to revenue given $0.0M reported in each period?
• What is the company's current cash runway, since cash fell from $139.5M to $48.3M in one year against a $-146.7M FCF?
• What is the debt position, given debt is listed as N/A for every period?
• What drove the 52-week decline from $36.26 to $6.24, and is that reflected in the rating's forensic inputs?
• Who are the institutional and insider holders behind the whale and insider pillar scores, given no holder data is provided?